Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00747643|
Recruitment Status : Completed
First Posted : September 5, 2008
Results First Posted : November 29, 2011
Last Update Posted : December 16, 2013
|Condition or disease||Intervention/treatment|
|Tobacco Dependence||Drug: varenicline Drug: placebo|
We proposed the following primary hypotheses:
- Tonic (i.e., non-cue-provoked) craving levels would be lower in participants receiving varenicline versus placebo.
- Cue-provoked cravings (self-report and physiological responding) would be lower in participants receiving varenicline versus placebo. (Secondary indices of craving include heart rate and skin conductance.)
- The two primary indices of nicotine reward/reinforcement (mCEQ and choice index) would be lower in participants receiving varenicline versus placebo. (Secondary indices of nicotine reinforcement include smoking topography variables.)
A final sample of 100 non-treatment seeking daily smokers were recruited from the Tampa-St. Petersburg-Clearwater Metropolitan Area via paid advertisements in, and press releases to, local newspapers, as well as targeted outdoor advertising via flyers (e.g., on public transportation).
Following the screening session, participants were randomly assigned to receive either varenicline or placebo medication.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||163 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement|
|Study Start Date :||September 2008|
|Primary Completion Date :||August 2010|
|Study Completion Date :||August 2010|
Active Comparator: Varenicline
For participants in the varenicline group, the medication doses followed the recommended dose schedule for the first 15 days of treatment: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day on days 8-15.
Participants in this group received varenicline according to the schedule in the Arm Description.
Other Name: Chantix™
Placebo Comparator: Placebo
Participants in this group received a placebo instead of medication. The placebo was taken once a day on days 1-3, twice a day on days 4-15.
Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
- Tonic Craving Score (QSU) Based on Self Reports [ Time Frame: 3 weeks per participant ]Tonic Craving 1 (lowest) to 7 (highest). The Questionnaire of Smoking Urges (QSU), our primary measure of tonic craving, is a 32-item instrument, including 2 separate factor scales that roughly correspond to the desire to smoke for its pleasurable effects (positive reinforcement) or to remove unpleasant feelings of negative affect or withdrawal (negative reinforcement) (Tiffany and Drobes 1991). Following overnight abstinence, each session included assessment of tonic craving, reactivity (including craving) to smoking cues.
- Cue-provoked Cravings [ Time Frame: 3 weeks per participant ]Strength of Craving 0 (lowest) to 20 (highest). One item 0 - 20 Likert scale "How strong was your craving to smoke a cigarette?"
- Smoking Topography - Number of Puffs on a Cigarette [ Time Frame: 3 weeks per participant ]# Puffs = total number of puffs taken at Assessment Session.
- A Measure of the Subjective Expected Value of a Cigarette [ Time Frame: 3 weeks per participant ]The cigarette choice procedure (Kidorf, Stitzer, and Griffiths, 1995) is a measure of the desire to smoke a cigarette. Participants are asked to hypothetically choose between smoking a cigarette now or receiving a small amount of money (from 10 cents up to $6 in increments of 10 cents). A crossover ($) value, at and above which participants prefer money, is obtained (Reid, Palmar, Raghavan, and Flammino, 2007).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00747643
|United States, Florida|
|H. Lee Moffitt Cancer Center and Research Institute|
|Tampa, Florida, United States, 33612|
|Principal Investigator:||Thomas Brandon, Ph.D.||H. Lee Moffitt Cancer Center and Research Institute|